ImmuCell Corporation Stock Price and Value Analysis

Should you buy ImmuCell Corporation stock? (NasdaqCM:ICCC). Let's see how it does in our automated value investing analysis system.

AdvantagesDisadvantagesNeutral
  • This company has stable growth.
  • This company is less known than others.
  • This company is not making money.
  • This stock looks overpriced.
  • This company pays no dividend.

ICCC Free Cash Flow Trend

Hmm, we can't give any reliable projection for ImmuCell Corporation's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

Free Cash Flow trendline for ImmuCell Corporation

Inside the ICCC Numbers

ICCC Price
(ImmuCell Corporation stock price per share)
$7.25
[?] PE Ratio versus Sector 2819% higher than other Healthcare stocks
[?] PE Ratio versus Industry 923% higher than other Biotechnology stocks
[?] Free Cash Flow Jitter 15%

Is ImmuCell Corporation Stock on Sale?

Based on our analysis, we believe that you should not buy ImmuCell Corporation right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy ICCC Stock?

Does ImmuCell Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.